UniSuper Management Pty Ltd Acquires 4,382 Shares of Hologic, Inc. $HOLX

Key Points

• UniSuper Management Pty Ltd increased its stake in Hologic, Inc. by 14.4% in Q1, owning a total of $2.15 million in shares after additional purchases.
• Hologic's quarterly earnings of $1.08 EPS surpassed analysts' estimates, with revenue rising to $1.02 billion, reflecting a 1.2% year-over-year increase.
• Hologic's average analyst rating is a "Moderate Buy" with a target price averaging $78.00, following recent upgrades from multiple firms.

UniSuper Management Pty Ltd grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 14.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,810 shares of the medical equipment provider's stock after purchasing an additional 4,382 shares during the period. UniSuper Management Pty Ltd's holdings in Hologic were worth $2,150,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Scientech Research LLC acquired a new position in shares of Hologic during the 1st quarter valued at about $647,000. Sandler Capital Management increased its holdings in shares of Hologic by 20.9% during the 1st quarter. Sandler Capital Management now owns 53,824 shares of the medical equipment provider's stock valued at $3,325,000 after acquiring an additional 9,290 shares during the last quarter. Petrus Trust Company LTA acquired a new position in shares of Hologic during the 1st quarter valued at about $332,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Hologic by 10.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider's stock valued at $2,395,000 after acquiring an additional 3,520 shares during the last quarter. Finally, EP Wealth Advisors LLC increased its holdings in shares of Hologic by 8.4% during the 1st quarter. EP Wealth Advisors LLC now owns 9,828 shares of the medical equipment provider's stock valued at $607,000 after acquiring an additional 760 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

HOLX stock traded down $1.93 during trading on Friday, hitting $64.45. The company had a trading volume of 1,005,460 shares, compared to its average volume of 1,495,210. The company has a fifty day moving average price of $66.43 and a two-hundred day moving average price of $62.66. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The company has a market cap of $14.33 billion, a P/E ratio of 26.74, a P/E/G ratio of 2.41 and a beta of 0.57. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Wall Street Zen raised Hologic from a "hold" rating to a "buy" rating in a report on Sunday, September 7th. Evercore ISI lifted their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th. Morgan Stanley lifted their price objective on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and lifted their price objective for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.